White matter alterations within the brain are associated with cognitive impairment among individuals with and without major ...

A groundbreaking clinical trial has revealed that nerve-stimulating therapy can bring significant improvements to people with ...

Most of us have high expectations this time of year, everything from presents and family gatherings to fabulous feasts. But that doesn’t always pan out, leaving some patients ...

Discover Honey Singhs battle with bipolar disorder his struggles with paranoia and psychosis and the signs to watch out for ...

The company’s pipeline products include CYB003, CYB004 and CYB005. Its CYB003 is a deuterated psiloCybin analog that treats major depressive disorder and alcohol use disorder; CYB004 is a deuterated ...

Learn why we need vitamin D to manage symptoms of Seasonal Affective Disorder, and why more research is needed.

Lysergic acid diethylamide is under clinical development by Mind Medicine MindMed and currently in Phase II for Major Depressive Disorder.

TMS has been approved for treating clinical depression in adults since 2008. Recent effectiveness data with adolescents shows ...

Neumora Therapeutics to release phase 3 data on Navacaprant for MDD treatment in 2024. Check out NMRA's catalysts that might ...

MindMed currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks from the biotech sector are Castle Biosciences, Inc. CSTL, CytomX Therapeutics CTMX and Spero Therapeutics SPRO, each ...

P rogress in addressing mental health is notoriously slow and mostly incremental. Breakthrough treatments tend to be rare, ...

The following is a summary of “Service coverage for major depressive disorder: estimated rates of minimally adequate ...